Brain Behavior & Immunity - Health, Год журнала: 2024, Номер 41, С. 100864 - 100864
Опубликована: Сен. 16, 2024
Язык: Английский
Schizophrenia Bulletin, Год журнала: 2024, Номер 50(3), С. 496 - 512
Опубликована: Март 7, 2024
Abstract This article describes the rationale, aims, and methodology of Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ). is largest international collaboration to date that will develop algorithms predict trajectories outcomes individuals at clinical high risk (CHR) for psychosis advance development use novel pharmacological interventions CHR individuals. We present a description participating research networks data processing analysis coordination center, their processes harmonization across 43 sites from 13 countries (recruitment North America, Australia, Europe, Asia, South America), flow quality assessment processes, analyses, transfer National Institute Mental Health (NIMH) Data Archive (NDA) by community. In an expected sample approximately 2000 640 matched healthy controls, AMP SCZ collect clinical, environmental, cognitive along with multimodal biomarkers, including neuroimaging, electrophysiology, fluid biospecimens, speech facial expression samples, measures derived digital health technologies smartphone-based daily surveys, passive sensing as well actigraphy. The study investigate range over 2-year period, transition psychosis, remission or persistence status, attenuated positive symptoms, persistent negative mood anxiety psychosocial functioning. global reach its harmonized innovative methods promise catalyze new treatments address critical unmet public needs in
Язык: Английский
Процитировано
22
Antioxidants, Год журнала: 2024, Номер 13(6), С. 709 - 709
Опубликована: Июнь 12, 2024
Psychosis, defined as a set of symptoms that results in distorted sense reality, is observed several psychiatric disorders addition to schizophrenia. This paper reviews the literature relevant underlying neurobiology psychosis. The dopamine hypothesis has been major influence study neurochemistry psychosis and development antipsychotic drugs. However, it became clear early on other factors must be involved dysfunction In current review, reported how these factors, namely dysregulation neurotransmitters [dopamine, serotonin, glutamate, γ-aminobutyric acid (GABA)], neuroinflammation, glia (microglia, astrocytes, oligodendrocytes), hypothalamic–pituitary–adrenal axis, gut microbiome, oxidative stress, mitochondrial contribute interact with one another. Research increased knowledge complexity psychotic disorders. Potential new pharmacotherapies, including combinations drugs (with pre- probiotics some cases) affecting mentioned above, have suggested. Similarly, putative biomarkers, particularly those related immune system, proposed. Future research both pharmacotherapy biomarkers will require better-designed studies conducted an all stages consider confounders such sex differences comorbidity.
Язык: Английский
Процитировано
11
Antioxidants, Год журнала: 2023, Номер 12(4), С. 975 - 975
Опубликована: Апрель 21, 2023
Schizophrenia is a worldwide mental illness characterized by alterations at dopaminergic and glutamatergic synapses resulting in global dysconnectivity within between brain networks. Impairments inflammatory processes, mitochondrial functions, energy expenditure, oxidative stress have been extensively associated with schizophrenia pathophysiology. Antipsychotics, the mainstay of pharmacological treatment all sharing common feature dopamine D2 receptor occupancy, may affect antioxidant pathways as well protein levels gene expression. Here, we systematically reviewed available evidence on antioxidants’ mechanisms antipsychotic action impact first- second-generation compounds functions stress. We further focused clinical trials addressing efficacy tolerability antioxidants an augmentation strategy treatment. EMBASE, Scopus, Medline/PubMed databases were interrogated. The selection process was conducted respect Preferred Reporting Items for Systematic Reviews Meta-Analyses (PRISMA) criteria. Several proteins involved cell viability, metabolism, regulation systems reported to be significantly modified differences drugs. Finally, cognitive psychotic symptoms patients schizophrenia, although only preliminary, results indicate that studies are warranted.
Язык: Английский
Процитировано
16
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy, Год журнала: 2023, Номер 43(12), С. 1364 - 1396
Опубликована: Окт. 16, 2023
Clozapine is an effective antipsychotic medication used for treatment-resistant schizophrenia. However, it underutilized due to rigorous hematologic monitoring requirements and many adverse drug reactions. Publications have highlighted the occurrence of inflammatory reactions, some life-threatening, particularly during early stages clozapine treatment. Although guidelines suggested processes initiation, screening in clinical practice not universal. This systematic review aimed investigate relationship between inflammation assess importance A comprehensive literature search yielded 6915 unique publication records after removal duplicates. After a process, 75 publications were included review, which focused on three main aspects: (i) impact markers, (ii) cardiac other organ function clozapine-associated processes, (iii) non-specific signs symptoms inflammation. Elevated levels C-reactive protein (CRP) several proinflammatory cytokines been observed association with practicality measuring specific markers remains uncertain. Current evidence supports CRP first 4-8 weeks treatment, especially facilitate myocarditis screening. Further research needed establish clinically relevant thresholds intervention. The implementation protocols phase treatment may mitigate reactions allow continued use clozapine. Future studies should also explore pneumonia, as well metabolism predict need dose adjustment. These endeavors development evidence-based
Язык: Английский
Процитировано
16
Molecular Psychiatry, Год журнала: 2024, Номер 29(8), С. 2571 - 2574
Опубликована: Март 7, 2024
Язык: Английский
Процитировано
7
Frontiers in Psychiatry, Год журнала: 2024, Номер 15
Опубликована: Фев. 8, 2024
Keywords: inflammation, schizophrenia, biomarkers, psychiatric genetics, neurobiology, neuroinflammation, psychotic disorders
Язык: Английский
Процитировано
6
Current Psychiatry Reports, Год журнала: 2024, Номер 26(5), С. 253 - 263
Опубликована: Апрель 16, 2024
Язык: Английский
Процитировано
6
Schizophrenia Research, Год журнала: 2023, Номер 264, С. 71 - 80
Опубликована: Дек. 14, 2023
Язык: Английский
Процитировано
14
Development and Psychopathology, Год журнала: 2024, Номер unknown, С. 1 - 11
Опубликована: Фев. 26, 2024
Research on serious mental disorders, particularly psychosis, has revealed highly variable symptom profiles and developmental trajectories prior to illness-onset. As Dante Cicchetti pointed out decades before the term "transdiagnostic" was widely used, pathways psychopathology emerge in a system involving equifinality multifinality. Like most other psychological psychosis is associated with multiple domains of risk factors, both genetic environmental, there are many transdiagnostic that can lead psychotic syndromes. In this article, we discuss our current understanding heterogeneity etiology its implications for approaches conceptualizing research. We highlight need examining factors at levels increase emphasis as key etiologic subtypes. This will be increasingly feasible now large, longitudinal datasets becoming available researchers have access more sophisticated analytic tools, such machine learning, which identify homogenous subtypes ultimate goal enhancing options treatment preventive intervention.
Язык: Английский
Процитировано
5
European Archives of Psychiatry and Clinical Neuroscience, Год журнала: 2024, Номер 274(7), С. 1671 - 1679
Опубликована: Март 16, 2024
Язык: Английский
Процитировано
5